Drugs / PF-03715455
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01314885 | Jan → Dec 2011 | chronic obstructive pulmonary disease | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02366637 | Jan → May 2015 | chronic obstructive pulmonary disease | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02219048 | Nov 2014 → May 2015 | asthma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01186757 Comparator | Aug 2010 → Jan 2011 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-03715455 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02366637 ↗ |
| Known as | Pf-3715455 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1938400 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL1938400 ↗ |
| Modality | Small molecule | — CHEMBL1938400 ↗ |
| Route | Inhaled | “Multiple Inhaled Doses of PF-03715455” NCT01186757 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL1938400 ↗ |